MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis

Rheumatology (Oxford). 2019 Jul 1;58(7):1302-1303. doi: 10.1093/rheumatology/kez078.

Authors

Erika Huijser¹, Cornelia G van Helden-Meeuwsen¹, Noortje Groot², Iris L A Bodewes¹, M Javad Wahadat^{1

2}, Marco W J Schreurs¹, Paul L A van Daele^{1

3}, Virgil A S H Dalm^{1

3}, Jan A M van Laar^{1

3}, P Martin van Hagen^{1

3}, Matti Waris⁴, Sylvia Kamphuis², Marjan A Versnel¹

Affiliations

¹ Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Department of Paediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
³ Department of Internal Medicine, Division of Clinical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁴ Department of Virology, University of Turku, Turku, Finland.

PMID: 30879072
DOI: 10.1093/rheumatology/kez078

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / blood
Case-Control Studies
Humans
Interferon Type I / immunology*
Lupus Erythematosus, Systemic / immunology*
Myxovirus Resistance Proteins / blood*
Scleroderma, Systemic / immunology*

Substances

Biomarkers
Interferon Type I
MX1 protein, human
Myxovirus Resistance Proteins